Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Chicago, IL
NPI: 1316906779Primary Practice Location
NORTHWESTERN MEMORIAL HOSPITAL
250 E Superior St, Chicago, IL
Primary Employer
Northwestern Medical Group
nm.org
HQ Phone
Get M.D. Jamile's Phone NumberMobile
Get M.D. Jamile's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
1991 - 2026
American Board of Internal Medicine
Hematology
American Board of Pathology
Anatomic Pathology & Clinical Pathology
University of Chicago
Fellowship • Hematology and Medical Oncology
1996 - 1999
McGaw Medical Center of Northwestern University
Residency • Internal Medicine
1991 - 1995
University of Chicago (Endeavor Health – NorthShore Hospitals)
Residency • Pathology-Anatomic and Clinical
1988 - 1991
University of Aleppo Faculty of Medicine
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 44 | 64 |
| 2 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 34 | 34 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 31 | 63 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
| 5 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 20 | 29 |
The May-Hegglin anomaly: a rare cause of a common complaint
Authors: Priyanka Reddy, Revathi Kollipara, Jamile M. Shammo, Jerome Loew
Publication Date: 2021-03
Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.
Authors: Reem Karmali, Stephanie Gregory
Publication Date: 2016-08-29
Lead Sponsor: Traws Pharma, Inc.
Intervention / Treatment: DRUG: Azacitidine, DRUG: oral rigosertib
Lead Sponsor: Astex Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: ASTX727, DRUG: Dacogen
Lead Sponsor: Traws Pharma, Inc.
Intervention / Treatment: DRUG: best supportive care (BSC), DRUG: rigosertib, DRUG: Any approved or standard-of-care therapy
